Content about Fenofibrate

May 17, 2013
Mylan launches cholesterol drug

Mylan has launched a generic drug for treating cholesterol, the company said.

PITTSBURGH — Mylan has launched a generic drug for treating cholesterol, the company said Friday.

Mylan announced the launch of fenofibrate tablets in the 48 mg and 145 mg strengths. The drug is used to reduce so-called "bad" low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B while increasing "good" high-density lipoprotein cholesterol in adults with primary hyperocholesterolemia or mixed dyslipidemia.

February 25, 2013
Mylan ships cholesterol drug

Mylan has begun shipping a generic drug for cholesterol, the company said Monday.

PITTSBURGH — Mylan has begun shipping a generic drug for cholesterol, the company said Monday.

Mylan said a subsidiary had started shipping fenofibrate capsules in the 43-mg and 130-mg strengths. The drug is a generic version of Lupin Atlantis Holdings Antara, used in combination with diet to reduce elevated bad cholesterol and other blood lipids and increase beneficial HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia.

November 21, 2012
Lupin launches generic fenofibrate

Lupin Pharmaceuticals has launched a generic drug for cholesterol disorders, the company said.

BALTIMORE — Lupin Pharmaceuticals has launched a generic drug for cholesterol disorders, the company said.

Lupin announced the launch of fenofibrate tablets in the 48-mg and 145-mg strengths. The drug is used to treat hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia.

The drug is a generic version of Abbott's Tricor, which had sales of $1.26 billion during the 12-month period ended in June, according to IMS Health.

November 1, 2011
Impax reports sales, profit increases in third quarter

Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

HAYWARD, Calif. — Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

The latest sales figures represented a $12.2 million increase over third quarter 2010, while profits were $4.2 million higher.

June 6, 2011
FDA finds manufacturing issues at Impax's Hayward, Calif., plant

The Food and Drug Administration has found manufacturing issues at a plant owned by generic drug maker Impax Labs, the drug maker said Monday.

HAYWARD, Calif. — The Food and Drug Administration has found manufacturing issues at a plant owned by generic drug maker Impax Labs, the drug maker said Monday.

August 26, 2010
Study says grapefruit can help treat diabetes

According to a recent study published in the science journal PloS One, eating grapefruit could...

July 22, 2010
Study: Two therapies may slow diabetic retinopathy in Type 2 diabetes

In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow...

WINSTON-SALEM, N.C. In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

May 2, 2010
Watson confirms patent challenge for Trilipix generic

Drug maker Abbott has sued a Watson Pharmaceuticals subsidiary over its attempt to market a...